Latest News and Press Releases

Using an optimized once-daily (QD) regimen, MDR-001 achieved a body weight reduction of 8.9% over 12 weeks.

Mindrank delivered a keynote presentation entitled “AI-Designed Oral GLP-1RA: First-in-Class Phase IIb Clinical Readouts and Translational Insights”.

BlossomHill Therapeutics, Inc. today announced the first patient dosed in the expansion cohorts of the SOLARA trial, the first-in-human trial of BH-30643.

MDR-001 achieved statistically significant weight reductions of 8.2% to 10.3% at 24 weeks compared to 2.5% with placebo (p<0.00001), with up to 48.1% of participants achieving ≥10% weight loss.No...

MENLO PARK, Calif. and CAMBRIDGE, Mass., June 18, 2025 (GLOBE NEWSWIRE) -- Synfini Inc., a leader in AI-driven drug discovery, and O2nix Bio, a pioneering biotech company advancing prooxidant...

Paris, May 28, 2025 (GLOBE NEWSWIRE) -- One of the biggest challenges facing biologic drug developers are varying efficacy and the dangers of side effects. Biotechnology company kyron.bio today...

Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis...

Dublin, Feb. 27, 2024 (GLOBE NEWSWIRE) -- The "Artificial Intelligence / AI in Drug Discovery Market by Offering, Process (Target selection, Validation, Lead Generation, Optimization), Drug Design...

Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "YG1699 Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. Understanding the future market...

MENLO PARK, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Synfini, Inc., a pioneer in agile chemistry whose advanced, automated molecular discovery platform is transforming drug discovery, today...